MDCO's Carbavance meets in Phase III cUTI study

The Medicines Co. (NASDAQ:MDCO) said Carbavance meropenem/vaborbactam was non-inferior to tazobactam/piperacillin on both the FDA- and EMA-specified primary endpoints in the 550-patient, Phase III TANGO 1 trial to

Read the full 281 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE